$2.83
-0.02 (-0.70%)
Open$2.87
Previous Close$2.85
Day High$2.89
Day Low$2.74
52W High$3.65
52W Low$1.63
Volume—
Avg Volume664.5K
Market Cap193.53M
P/E Ratio—
EPS$-1.35
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+485.5% upside
Current
$2.83
$2.83
Target
$16.57
$16.57
$14.06
$16.57 avg
$23.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.33M | 18.18M | 17.68M |
| Net Income | -947,103 | -802,247 | -886,084 |
| Profit Margin | -4.9% | -4.4% | -5.0% |
| EBITDA | -1,287,077 | -1,124,832 | -1,061,399 |
| Free Cash Flow | -739,760 | -479,993 | -441,081 |
| Rev Growth | +21.0% | +13.7% | -3.4% |
| Debt/Equity | 0.36 | 0.44 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |